An article by one of our partner physicians, Dr. Freddy Gnangnon in Benin, was recently published in Clinical Surgical Oncology. It’s about the management of locally advanced gastrointestinal stromal tumors and how providing access to treatment free of charge improves survival outcomes.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
At the 13th Annual SOHO Meeting in Houston (Sept 3–6, 2025), Andrielle Yost, Associate Director of Public Sector Engagement at The Max Foundation, discusses the work the organization is doing to improve access to chronic lymphocytic leukemia (CLL) treatment for patients in low- and middle-income countries (LMICs). Watch the interview here. You can also watch….
The Max Foundation has renewed and expanded its treatment-access agreement with Incyte in Europe. The agreement will now provide treatment access for up to 50 patients in Eastern Europe and Central Asia.
The Max Foundation and Tanner Pharma Group have partnered to create an innovative distribution model to deliver oncology products to patients in need.
